Optic Neuritis Treatment Market - Growth, Trends, and Forecasts (2023 - 2028)

The optic neuritis treatment market is expected to register a CAGR of 4.1% over the forecast period.

The outbreak of the pandemic impacted the market. The COVID-19 infection increased the prevalence rate of optic neuritis. For instance, as per the NCBI research study published in December 2021, post-COVID optic neuritis was identified as a possible neurological complication of the novel coronavirus infection. The same study also reported that females were more affected by optic neuritis and retinal complications. Thus, the increase in cases of optic neuritis due to COVID-19 positively impacted the market as it increased the demand for optic neuritis treatment. However, the cancellations of ophthalmology services slightly adversely impacted the market. For instance, as per the journal published by the Eye Surgery Center of Paducah in 2022, during the initial months of the pandemic, of all medical service lines, ophthalmology had the greatest patient volume loss. The same source also stated that ophthalmology lost 81.0% of patient volume year-over-year when comparing two-week volumes in March and April 2020 versus the same period in previous years. Although, with the resumption of ophthalmology services and increasing number of cases of optic neuritis, the market started to gain traction and is expected to maintain the upward trend over the forecast period.

The increasing prevalence of optic neuritis is one of the major factors propelling market growth over the forecast period. In addition, according to the Optic Neuritis Foundation Inc. report published in 2021, an estimated 15.0% to 20.0% of the people suffering from optic neuritis are likely to end up suffering from multiple sclerosis. Furthermore, as per the NCBI study published in 2021, optic neuritis affects roughly 70.0% of patients with multiple sclerosis and is one of the presenting symptoms in approximately 25.0% of individuals. The same source also stated that women were affected twice as often as men. Furthermore, as per the PLOS journal published in June 2022, optic neuritis is a relatively common disease with an estimated lifetime risk of 0.6 per 1000 and an estimated prevalence of 1-5 per 100,000 per year. In addition, according to the UpToDate Journal published in December 2022, the incidence of optic neuritis is highest in populations located at higher latitudes, such as in the northern United States and western Europe, and is lowest in regions closer to the equator. In the United States, studies have estimated the annual incidence of optic neuritis to be as high as 6.4 per 100,000. Thus, such an increasing prevalence of optic neuritis is expected to increase the demand for optic neuritis treatment, thereby propelling market growth over the forecast period.

Furthermore, increasing research work related to optic neuritis treatment is also anticipated to propel market growth. For instance, as per the BMC journal published in December 2021, mesenchymal stem cell (MSC) therapy is a promising approach that results in remyelination and neuroprotection of axons and has demonstrated success in clinical studies in other neuro-degenerative diseases. The study also stated that mesenchymal stem cell-derived extracellular vesicles can be considered as an emerging treatment strategy for optic neuritis. Similarly, as per the research study published by the BMC journal in September 2021, the Optic Neuritis Treatment Trial (ONTT) combined corticosteroid regimen has demonstrated improved conduction in the visual pathways of patients with first-episode optic neuritis. Therefore, increasing research work related to optic neuritis treatment is expected to spur market growth over the forecast period.

However, side effects associated with the treatment may hinder the market's growth over the forecast period.

Optic Neuritis Treatment Market Trends

Steroidal Therapy Segment is Expected to Witness Considerable Growth Over the Forecast Period

Steroidal therapy includes corticosteroid drugs used to treat optic neuritis, which have proven efficacy for decades. Corticosteroids are a type of anti-inflammatory drug. They are typically used to treat optic neuritis. Specific corticosteroids include the medications cortisone and prednisone. Corticosteroids are man-made drugs that closely resemble cortisol, a hormone that the adrenal glands naturally produce. Corticosteroids are often referred to by the shortened term "steroids." Steroids might be given locally, to the precise place where a problem exists, or systemically.

The increasing cases of optic neuritis and the increasing use of steroidal therapy for the treatment are the major factors propelling the segment's growth. For instance, according to the Optic Neuritis Foundation Inc. report published in 2021, adults between the ages of 18 and 45 are most susceptible to optic neuritis. Moreover, females are said to be more inclined to optic nerve inflammation as compared to males. However, only 3.0% of the population suffering from optic neuritis is expected to lose complete vision and go blind. Furthermore, the increasing use of steroidal therapy for the treatment of optic neuritis is also expected to spur segment growth. For instance, as per the research study published in JAMA Neurology in 2021, intravenous (IV) administration of corticosteroids is considered the standard of care in the treatment of acute optic neuritis. Furthermore, as per the research study published by Cochrane in 2021, corticosteroids are widely used in the treatment of optic neuritis due to their anti-inflammatory effects. Moreover, according to the research study published by Science Direct in October 2021, steroidal therapy is considered the first line of treatment for optic neuritis. Thus, increasing the use of steroidal therapy for the treatment of optic neuritis is expected to boost segment growth over the forecast period.

North America is Expected to Hold a Significant Share Over the Forecast Period

North America is expected to hold a significant share in the optic neuritis treatment market due to the high disease prevalence, availability of reimbursement, and growing awareness among the population regarding multiple sclerosis and optic neuritis in the region. For instance, as per the study published in the Journal of Neurology in 2021, the annual incidence of optic neuritis in the United States is found to be around 5/1,000,000, with an estimated prevalence of 115/1,000,000. Furthermore, technological advancement, the launch of new treatment options, increasing healthcare spending, and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.

Key product launches, a high concentration of market players or manufacturers' presence, acquisitions and partnerships among major players, and product approvals in the United States are some of the factors driving the growth of the optic neuritis market in the country. For instance, in August 2020, the U.S. FDA approved Enspryng (satralizumab-mwge) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with a particular antibody in patients who are anti-aquaporin-4 or AQP4 antibody-positive. Enspryng is the third approved treatment for the disorder. Similarly, in August 2020, Novartis announced that the US FDA had approved Kesimpta (ofatumumab, formerly OMB157) as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis (RMS) in adults. Thus, such product approvals may create new opportunities for the market; therefore, considerable market growth is anticipated in the United States over the forecast period.

Optic Neuritis Treatment Industry Overview

The optic neuritis treatment market is fragmented and consists of several major players. Some of the major players that are currently dominating the market are Pfizer Inc., Mallinckrodt Pharmaceuticals, Novartis AG, Teijin Pharmaceutical Limited, AbbVie (Allergan PLC), and AdvaCare Pharma, among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.